SmartGene and Illumina Collaborate to Promote Broad Adoption of Next Generation Sequencing for Routine Testing Across Multiple Markets
Unterägeri, Switzerland _ SmartGene, a leading provider of bioinformatics Software-as-a-Service applications (SaaS Apps), today announced a new collaboration with Illumina, a global leader in DNA sequencing and array-based technologies, to enable broad adoption of Next Generation Sequencing (NGS) for routine analysis in infectious diseases and industrial markets. The scope of the collaboration includes clinical microbiology, food testing, and biopharmaceutical manufacturing quality control. The collaboration will address the emerging opportunity to offer more holistic, application-specific solutions which are easier for routine laboratories to implement.
“We are delighted to collaborate with Illumina, to accelerate the adoption of SmartGene’s SaaS Apps and to broaden the use of NGS in routine testing,” said Stefan Emler, MD, SmartGene’s founder and CEO. “NGS technologies have revolutionized life science research; however, applying NGS to routine testing has been limited so far. SmartGene’s SaaS Apps are “bioinformatics solutions for non-bioinformaticians”, enabling routine laboratories to adopt NGS technologies more easily.”
“We are proud to support SmartGene in enabling laboratories to take advantage of the power of Next Generation Sequencing in their routine work, democratizing its use across multiple market segments,” said Paula Dowdy, Senior Vice President and General Manager of Illumina for Europe, the Middle East, and Africa.
About SmartGene
SmartGene is a bioinformatics application service provider delivering secure, integrated, SaaS Apps for the analysis, interpretation, and management of genetic data. The Cloud Apps incorporate SmartGene’s proprietary, validated Centroids reference databases, and enable clinical management and epidemiological monitoring of infectious diseases involving bacteria, fungi, and viruses. Apps are also provided for food authenticity, integrity, and safety testing, and for quality management of biopharmaceutical products. Find out more at www.smartgene.com.
SmartGene contact:
David Ellis
